<生产厂家价格>

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮用途

CCT 007093是PPM1D抑制剂,能选择性地降低人肿瘤细胞株活力。

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮名称

[ CAS 号 ]:
176957-55-4

[ 中文名 ]:
(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮

[ 英文名 ]:
CCT007093

[英文别名 ]:

(2E,5E)-2,5-Bis(2-thienylmethylene)cyclopentanone
CCT007093

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮生物活性

[ 描述 ]:

CCT 007093是PPM1D抑制剂,能选择性地降低人肿瘤细胞株活力。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 癌症

[参考文献]

[1]. Rayter S, et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 2008 Feb 14;27(8):1036-44.

[2]. Buss MC, et al. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol. 2012 Apr;14(4):440-58.

[3]. Lee JS, et al. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes. J Dermatol Sci. 2014 Feb;73(2):125-34.

[相关活性小分子]

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮物理化学性质

[ 密度 ]:
1.4±0.1 g/cm3

[ 沸点 ]:
484.7±45.0 °C at 760 mmHg

[ 熔点 ]:
222-223℃

[ 分子式 ]:
C₁₅H₁₂OS₂

[ 分子量 ]:
272.385

[ 闪点 ]:
246.9±28.7 °C

[ 精确质量 ]:
272.032959

[ PSA ]:
73.55000

[ LogP ]:
5.18

[ 外观性状 ]:
粉末

[ 蒸汽压 ]:
0.0±1.2 mmHg at 25°C

[ 折射率 ]:
1.748

[ 储存条件 ]:
2~8°C

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮MSDS

详细MSDS(安全技术说明书)

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P261-P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi

[ 风险声明 (欧洲) ]:
36/37/38

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3.0

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮合成路线

详细合成路线

(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮文献

Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to γ-radiation.

Cell Death Dis. 4 , e744, (2013)

Wild-type p53-induced phosphatase 1 (Wip1) is a p53-inducible serine/threonine phosphatase that switches off DNA damage checkpoint responses by the dephosphorylation of certain proteins (i.e. p38 mito...

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Breast Cancer Res. 12 , R41, (2010)

Paclitaxel is a widely used drug in the treatment of patients with locally advanced and metastatic breast cancer. However, only a small portion of patients have a complete response to paclitaxel-based...

更多文献